$OVID
Ovid Therapeutics Inc.

2023 Q4 Form 10-Q Financial Statement

#000162828023036564 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $141.6K $109.0K
YoY Change 205.88% 881.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.688M $6.800M
YoY Change 15.38% -10.9%
% of Gross Profit
Research & Development $10.64M $5.333M
YoY Change 91.53% 2.88%
% of Gross Profit
Depreciation & Amortization $140.5K $104.3K
YoY Change -24.04% 2.21%
% of Gross Profit
Operating Expenses $18.33M $12.14M
YoY Change 50.01% -5.28%
Operating Profit -$12.03M
YoY Change -6.05%
Interest Expense $2.866M $800.0K
YoY Change 168.35% -22.79%
% of Operating Profit
Other Income/Expense, Net $776.4K
YoY Change -488.22%
Pretax Income -$15.32M -$11.25M
YoY Change 33.18% -5.98%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$15.32M -$11.25M
YoY Change 33.18% -5.98%
Net Earnings / Revenue -10823.7% -10325.94%
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.22 -$0.16
COMMON SHARES
Basic Shares Outstanding 70.68M shares 70.60M shares
Diluted Shares Outstanding 70.62M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $105.8M $87.07M
YoY Change -17.96% -36.84%
Cash & Equivalents $27.04M $57.44M
Short-Term Investments $78.79M $29.64M
Other Short-Term Assets $3.764M $4.600M
YoY Change 58.21% 74.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $109.6M $91.71M
YoY Change -16.58% -34.72%
LONG-TERM ASSETS
Property, Plant & Equipment $768.8K $856.5K
YoY Change -33.03% -26.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.63M $16.10M
YoY Change 245.6% 215.69%
Other Assets $209.6K $248.7K
YoY Change -19.76% -9.73%
Total Long-Term Assets $34.43M $33.32M
YoY Change 44.14% 35.79%
TOTAL ASSETS
Total Short-Term Assets $109.6M $91.71M
Total Long-Term Assets $34.43M $33.32M
Total Assets $144.0M $125.0M
YoY Change -7.24% -24.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.703M $1.217M
YoY Change 89.61% 17.76%
Accrued Expenses $6.525M $6.222M
YoY Change 44.85% 9.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.47M $8.663M
YoY Change 64.12% 28.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $44.76M $15.10M
YoY Change 179.69% -7.07%
Total Long-Term Liabilities $44.76M $15.10M
YoY Change 179.69% -7.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.47M $8.663M
Total Long-Term Liabilities $44.76M $15.10M
Total Liabilities $56.23M $23.74M
YoY Change 144.55% 3.29%
SHAREHOLDERS EQUITY
Retained Earnings -$277.9M -$262.5M
YoY Change 23.24% 22.66%
Common Stock $70.69K $70.68K
YoY Change 0.32% -99.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.80M $101.3M
YoY Change
Total Liabilities & Shareholders Equity $144.0M $125.0M
YoY Change -7.24% -24.24%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$15.32M -$11.25M
YoY Change 33.18% -5.98%
Depreciation, Depletion And Amortization $140.5K $104.3K
YoY Change -24.04% 2.21%
Cash From Operating Activities -$11.91M -$10.10M
YoY Change 29.82% -20.32%
INVESTING ACTIVITIES
Capital Expenditures $1.220K $0.00
YoY Change -98.06% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$48.51M -$4.300M
YoY Change 1081.42% 121.45%
Cash From Investing Activities -$48.52M -$4.400M
YoY Change 1063.59% 124.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.03M 200.0K
YoY Change -68983.92% 145.01%
NET CHANGE
Cash From Operating Activities -11.91M -10.10M
Cash From Investing Activities -48.52M -4.400M
Cash From Financing Activities 30.03M 200.0K
Net Change In Cash -30.40M -14.30M
YoY Change 127.02% -1.75%
FREE CASH FLOW
Cash From Operating Activities -$11.91M -$10.10M
Capital Expenditures $1.220K $0.00
Free Cash Flow -$11.91M -$10.10M
YoY Change 28.95% -20.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Liabilities
Liabilities
23736740 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22993250 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 ovid Preferred Stock Share Designated
PreferredStockShareDesignated
10000 shares
CY2022Q4 ovid Preferred Stock Share Designated
PreferredStockShareDesignated
10000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1250 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1250 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70680551 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70680551 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70466885 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
70681 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
70467 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
363768613 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
357770825 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3877 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-42187 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262543467 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225526542 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
101291951 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
132272564 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125028691 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155265814 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108972 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11102 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5332591 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5183253 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6805213 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7631705 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
12137804 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
12814958 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70430554 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70618609 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70430554 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11252386 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1250 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70466885 shares
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12028832 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12803856 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
776446 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
836085 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11252386 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11252386 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70618609 shares
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9085 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7335 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11261471 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11960436 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
132272564 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
66993 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1916518 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
47817 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13356209 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
120947682 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
223720 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1631027 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-9085 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11252386 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
101291951 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
33079 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324812 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
109548 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720217 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-90127 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14588414 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
152147496 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
81629 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1782043 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
7335 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
142050733 usd
us-gaap Net Income Loss
NetIncomeLoss
-37016925 usd
us-gaap Net Income Loss
NetIncomeLoss
-42664240 usd
ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
0 usd
ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
945366 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
501648 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-125721 usd
ovid Change In Accrued Interest And Accretion Of Discounts Short Term Investments
ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments
-1535648 usd
ovid Change In Accrued Interest And Accretion Of Discounts Short Term Investments
ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments
-821024 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5496194 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4827072 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
427760 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
327525 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
767423 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
614130 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-237884 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
650089 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2262388 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
156221 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-12491 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-56943 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-736347 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-6093980 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1718358 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1972044 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33868614 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46051395 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
53928189 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
108857928 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
110000000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30000000 usd
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
10000000 usd
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2500000 usd
ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
0 usd
ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
1000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26602 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104440 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
109637 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
251340 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45935572 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83713708 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
501808 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
224257 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
501808 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
224257 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12568766 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-129540846 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46798599 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189728285 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59367365 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60187439 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15791769 usd
ovid Conversion Of Short Term Note Receivable To Long Term Equity Investment
ConversionOfShortTermNoteReceivableToLongTermEquityInvestment
0 usd
ovid Conversion Of Short Term Note Receivable To Long Term Equity Investment
ConversionOfShortTermNoteReceivableToLongTermEquityInvestment
1000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
87100000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
222800000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262500000 usd
CY2023Q3 ovid Working Capital
WorkingCapital
83000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33900000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37000000 usd
CY2023Q3 ovid Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost
CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
87075565 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.
CY2023Q3 ovid Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Gain
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain
0 usd
CY2023Q3 ovid Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Loss
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss
3878 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
87071687 usd
CY2023Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
36700000 usd
CY2023Q3 us-gaap Cash
Cash
809178 usd
CY2023Q3 us-gaap Cash
Cash
809178 usd
CY2023Q3 ovid Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
56626797 usd
CY2023Q3 ovid Cash Equivalents Unrealized Holding Gains
CashEquivalentsUnrealizedHoldingGains
0 usd
CY2023Q3 ovid Cash Equivalents Unrealized Holding Losses
CashEquivalentsUnrealizedHoldingLosses
0 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
56626797 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29639590 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3878 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29635712 usd
CY2022Q4 us-gaap Cash
Cash
2853042 usd
CY2022Q4 us-gaap Cash
Cash
2853042 usd
CY2022Q4 ovid Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
42014804 usd
CY2022Q4 ovid Cash Equivalents Unrealized Holding Gains
CashEquivalentsUnrealizedHoldingGains
0 usd
CY2022Q4 ovid Cash Equivalents Unrealized Holding Losses
CashEquivalentsUnrealizedHoldingLosses
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
42014804 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
84175752 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
42187 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
84133565 usd
CY2022Q4 ovid Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost
CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
129043598 usd
CY2022Q4 ovid Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Gain
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain
0 usd
CY2022Q4 ovid Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Loss
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss
42187 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
129001411 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
899455 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
581381 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
856491 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147963 usd
CY2023Q3 us-gaap Depreciation
Depreciation
104323 usd
CY2022Q3 us-gaap Depreciation
Depreciation
102071 usd
us-gaap Depreciation
Depreciation
318074 usd
us-gaap Depreciation
Depreciation
187541 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
222051 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
222100 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41316 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53348 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109686 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
139984 usd
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2023Q3 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
19000 sqft
CY2023Q3 ovid Lessee Operating Lease Base Rent
LesseeOperatingLeaseBaseRent
2300000 usd
CY2022Q1 ovid Lessee Operating Lease Rent Payments Commencement Following This Period
LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod
P10M
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2023Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P9Y
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q3 ovid Lease Incremental Borrowing Rate
LeaseIncrementalBorrowingRate
0.0702
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14155246 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1224503 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15073284 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1625425 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
579076 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2316303 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2316303 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2316303 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2316303 usd
CY2023Q3 ovid Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
12347235 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22191523 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3837431 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3233802 usd
CY2023Q3 ovid Accrued Research And Development
AccruedResearchAndDevelopment
1745068 usd
CY2022Q4 ovid Accrued Research And Development
AccruedResearchAndDevelopment
395247 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
395813 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
682664 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
244078 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
192956 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6222390 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4504669 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
ovid Common Stock Number Of Votes For Each Share
CommonStockNumberOfVotesForEachShare
1 vote
us-gaap Dividends
Dividends
0 usd
us-gaap Dividends
Dividends
0 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1631028 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1782043 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5496194 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4827072 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5496194 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4827072 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12961238 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.13
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62158 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3004500 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.62
ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y5M8D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
134905 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
665956 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.52
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
9080083 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y1M9D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5268442 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11200000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M25D
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 ovid Collaboration And Option Agreement Research Plan And Budget Expected Costs
CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts
3000000 usd
CY2023Q2 ovid Collaboration And Option Agreement Research Plan And Budget Expected Costs
CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts
3500000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11252386 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
us-gaap Net Income Loss
NetIncomeLoss
-37016925 usd
us-gaap Net Income Loss
NetIncomeLoss
-42664240 usd
CY2023Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11252386 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11967771 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37016925 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42664240 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11252386 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11967771 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37016925 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42664240 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70618609 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70430554 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70544536 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70408657 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70618609 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70430554 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70544536 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70408657 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61

Files In Submission

Name View Source Status
0001628280-23-036564-index-headers.html Edgar Link pending
0001628280-23-036564-index.html Edgar Link pending
0001628280-23-036564.txt Edgar Link pending
0001628280-23-036564-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ovid-20230930.htm Edgar Link pending
ovid-20230930.xsd Edgar Link pending
ovid-20230930_g1.jpg Edgar Link pending
ovid2023q3exhibit311.htm Edgar Link pending
ovid2023q3exhibit312.htm Edgar Link pending
ovid2023q3exhibit321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
ovid-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ovid-20230930_lab.xml Edgar Link unprocessable
ovid-20230930_cal.xml Edgar Link unprocessable
ovid-20230930_pre.xml Edgar Link unprocessable
ovid-20230930_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending